The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism
Abstract
Drugs currently used for patients with Parkinson's disease provide temporary relief of symptoms but do not halt or slow the underlying neurodegenerative disease process. Increasing evidence suggests that neurons die in Parkinson's disease by a process called apoptosis, which may be triggered by mitochondrial impairment and oxidative stress. We report that two novel synthetic inhibitors of the tumor suppressor protein p53, pifithrin‐α (PFT‐α) and Z‐1‐117, are highly effective in protecting midbrain dopaminergic neurons and improving behavioral outcome in a mouse model of Parkinson's disease. Mice given intraperitoneal injections of PFT‐α or Z‐1‐117 exhibited improved motor function, reduced damage to nigrostriatal dopaminergic neurons and reduced depletion of dopamine and its metabolites after exposure to the toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). MPTP caused an increase in the level of the proapoptotic protein Bax, which was prevented by giving mice PFT‐α and Z‐1‐117. PFT‐α and Z‐1‐117 also suppressed Bax production and apoptosis in cultured dopaminergic cells exposed to MPP+. Our findings demonstrate a pivotal role for p53 in experimental parkinsonism and identify a novel class of synthetic p53 inhibitors with clinical potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Apoptosis in neurodegenerative disorders
Mattson, M. P. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35040009 · Cited by 1,605
Self-citationA Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999) · Science · doi:10.1126/science.285.5434.1733 · Cited by 1,270
Zhang, Y., Gao, J., Chung, K. K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240347797 · Cited by 982
Alam, Z. I., Jenner, A., Daniel, S. E., Lees, A. J., Cairns, N., Marsden, C. D., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031196.x · Cited by 845
Mandir, A. S., Przedborski, S., Jackson-Lewis, V., Wang, Z.-Q., Simbulan-Rosenthal, C. M., Smulson, M. E., Hoffman, B. E., Guastella, D. B., Dawson, V. L., & Dawson, T. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5774 · Cited by 382
Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease
de la Monte, S. M., Sohn, Y. K., & Wands, J. R. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00131-7 · Cited by 307
Ladenheim, B., Krasnova, I. N., Deng, X., Oyler, J. M., Polettini, A., Moran, T. H., Huestis, M. A., & Cadet, J. L. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.6.1247 · Cited by 131 · cited 1×
“Levels of dopamine, dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) were measured by high performance liquid chromotography–based analyes using methods described previously.(35,36) Contents of DA, DOPAC, HVA, 5-HT, 5-HIAA were calculated a…”
MethodSelf-citation
Cited by
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Ageing and neuronal vulnerability
Mattson, M. P., & Magnus, T. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1886 · Cited by 957
Self-citationApoptosis and Oxidative Stress in Neurodegenerative Diseases
Radi, E., Formichi, P., Battisti, C., & Federico, A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132738 · Cited by 630
What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 611
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
Self-citationTargeting programmed cell death in neurodegenerative diseases
Vila, M., & Przedborski, S. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1100 · Cited by 546
p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease
Bae, B.-I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y., Hayward, S. D., Moran, T. H., Montell, C., Ross, C. A., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.005 · Cited by 485
Mattson, M. P. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:3:2:65 · Cited by 475
Self-citationBrady, C. A., & Attardi, L. D. (2010) · Journal of Cell Science · doi:10.1242/jcs.064501 · Cited by 403
Culmsee, C., & Mattson, M. P. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.149 · Cited by 389
Self-citationThe pharmacological regulation of cellular mitophagy
Georgakopoulos, N. D., Wells, G., & Campanella, M. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2287 · Cited by 319
Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage
Perier, C., Tieu, K., Guégan, C., Caspersen, C., Jackson-Lewis, V., Carelli, V., Martinuzzi, A., Hirano, M., Przedborski, S., & Vila, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508215102 · Cited by 308
Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps
Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0309-3 · Cited by 287
Intracellular Aβ42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease
Ohyagi, Y., Asahara, H., Chui, D.-H., Tsuruta, Y., Sakae, N., Miyoshi, K., Yamada, T., Kikuchi, H., Taniwaki, T., Murai, H., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2637fje · Cited by 281
Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
Hay, D. A., Fedorov, O., Martin, S., Singleton, D. C., Tallant, C., Wells, C., Picaud, S., Philpott, M., Monteiro, O. P., Rogers, C. M., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja412434f · Cited by 277
Mitochondria in cell death: novel targets for neuroprotection and cardioprotection
Mattson, M. P., & Kroemer, G. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(03)00046-7 · Cited by 264
Self-citationRole of dietary iron restriction in a mouse model of Parkinson's disease
Levenson, C. W., Cutler, R. G., Ladenheim, B., Cadet, J. L., Hare, J., & Mattson, M. P. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.08.014 · Cited by 64
Self-citation(2007) · Cited by 33
Pak, K. J., Chan, S. L., & Mattson, M. P. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:3:2:119 · Cited by 26
“Recent studies have shown that homocysteine and folate deficiency promote neuronal degeneration in cell culture and animal models relevant to the pathogenesis of AD (Ho et al., 2001; White et al., 2001; Kruman et al., 2002) and Parkinson’s disease (Duan et al., 2002a).”
BackgroundMethodSelf-citation
Metadata
- Authors
- Duan, W., Zhu, X., Ladenheim, B., Yu, Q., Guo, Z., Oyler, J., Cutler, R. G., Cadet, J. L., Greig, N. H., & Mattson, M. P.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2002-09-24
- Volume
- 52
- Issue
- 5
- Pages
- 597-606
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2022762621
- Cited by
- 204
- References
- 8
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.